Compare XNCR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | PVLA |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2013 | 2013 |
| Metric | XNCR | PVLA |
|---|---|---|
| Price | $33.57 | $143.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | $43.83 | ★ $233.44 |
| AVG Volume (30 Days) | ★ 1.5M | 231.4K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,576,000.00 | $42,810,000.00 |
| Revenue This Year | $58.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 65.28 |
| 52 Week Low | $10.38 | $72.23 |
| 52 Week High | $40.60 | $179.95 |
| Indicator | XNCR | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 46.38 |
| Support Level | $22.80 | $139.09 |
| Resistance Level | $33.60 | $158.60 |
| Average True Range (ATR) | 2.08 | 10.44 |
| MACD | -0.54 | -2.18 |
| Stochastic Oscillator | 35.21 | 7.56 |
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.